Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Vor Biopharma Inc
(NQ:
VOR
)
0.9539
+0.0339 (+3.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vor Biopharma Inc
< Previous
1
2
Next >
Vor Bio Reports First Quarter 2023 Financial Results and Provides Company Update
May 11, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
April 18, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
March 23, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
February 21, 2023
From
Vor Biopharma
Via
GlobeNewswire
First AML Patient Transplanted with Vor Bio’s Trem-cel Demonstrated Durable Engraftment through Multiple Mylotarg™ Cycles at Initial Dose Level
February 16, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
January 19, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Present at B. Riley Securities’ 3rd Annual Oncology Conference
January 12, 2023
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Prices Underwritten Offering of Common Stock and Concurrent Private Placement for Aggregate Proceeds of $115.8 Million
December 07, 2022
From
Vor Biopharma
Via
GlobeNewswire
First AML Patient Successfully Transplanted with Vor Bio’s Investigational Trem-cel (VOR33) and Tolerated Mylotarg™
December 07, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 22, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Reports Third Quarter 2022 Financial Results and Provides Company Update
November 10, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
November 01, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer
October 12, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
October 11, 2022
From
Vor Biopharma
Via
GlobeNewswire
Vor Bio Initiates In-house Clinical Manufacturing at Cambridge, MA Headquarters
September 28, 2022
Facility to support clinical manufacturing for Vor Bio’s novel cell and genome engineering pipeline while reducing the time and cost required to manufacture its eHSC and CAR-T product candidates
From
Vor Biopharma
Via
GlobeNewswire
Akron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
March 22, 2022
From
Akron BioProducts
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.